BACKGROUND: It has been demonstrated that the partner and localizer of breast cancer 2 (PALB2) acts as a bridging molecule between the breast cancer 1 (BRCA1) and BRCA2 proteins and is responsible for facilitating BRCA2-mediated DNA repair. Truncating mutations in the PALB2 gene reportedly are enriched in patients with Fanconi anemia and breast cancer in various populations. METHODS: The authors evaluated the contribution of PALB2 germline mutations in 279 African American women with breast cancer, including 29 patients with a strong family history, 29 patients with a moderate family history, 75 patients with a weak family history, and 146 patients with nonfamilial or sporadic breast cancer. RESULTS: After direct sequencing of all the coding exons, exon/intron boundaries, and 5' and 3' untranslated regions of PALB2, 3 novel, monoallelic, truncating mutations (1.08%; 3 in 279 patients) were identified (c.758dupT [exon 4], c.1479delC [exon 4], and c.3048delT [exon 10]) together with 50 sequence variants, 27 of which were novel. None of the truncating mutations were identified in a group of 262 controls from the same population. CONCLUSIONS: PALB2 mutations were present in both familial and nonfamilial breast cancers among African Americans. Rare PALB2 mutations accounted for a small but substantial proportion of patients with breast cancer.
BACKGROUND: It has been demonstrated that the partner and localizer of breast cancer 2 (PALB2) acts as a bridging molecule between the breast cancer 1 (BRCA1) and BRCA2 proteins and is responsible for facilitating BRCA2-mediated DNA repair. Truncating mutations in the PALB2 gene reportedly are enriched in patients with Fanconi anemia and breast cancer in various populations. METHODS: The authors evaluated the contribution of PALB2 germline mutations in 279 African American women with breast cancer, including 29 patients with a strong family history, 29 patients with a moderate family history, 75 patients with a weak family history, and 146 patients with nonfamilial or sporadic breast cancer. RESULTS: After direct sequencing of all the coding exons, exon/intron boundaries, and 5' and 3' untranslated regions of PALB2, 3 novel, monoallelic, truncating mutations (1.08%; 3 in 279 patients) were identified (c.758dupT [exon 4], c.1479delC [exon 4], and c.3048delT [exon 10]) together with 50 sequence variants, 27 of which were novel. None of the truncating mutations were identified in a group of 262 controls from the same population. CONCLUSIONS:PALB2 mutations were present in both familial and nonfamilial breast cancers among African Americans. Rare PALB2 mutations accounted for a small but substantial proportion of patients with breast cancer.
Authors: Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter Journal: Nat Genet Date: 2006-12-31 Impact factor: 38.330
Authors: S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas Journal: J Med Genet Date: 2005-07-13 Impact factor: 6.318
Authors: Hannele Erkko; Bing Xia; Jenni Nikkilä; Johanna Schleutker; Kirsi Syrjäkoski; Arto Mannermaa; Anne Kallioniemi; Katri Pylkäs; Sanna-Maria Karppinen; Katrin Rapakko; Alexander Miron; Qing Sheng; Guilan Li; Henna Mattila; Daphne W Bell; Daniel A Haber; Mervi Grip; Mervi Reiman; Arja Jukkola-Vuorinen; Aki Mustonen; Juha Kere; Lauri A Aaltonen; Veli-Matti Kosma; Vesa Kataja; Ylermi Soini; Ronny I Drapkin; David M Livingston; Robert Winqvist Journal: Nature Date: 2007-02-07 Impact factor: 49.962
Authors: María J García; Victoria Fernández; Ana Osorio; Alicia Barroso; Gemma Llort; Conxi Lázaro; Ignacio Blanco; Trinidad Caldés; Miguel de la Hoya; Teresa Ramón Y Cajal; Carmen Alonso; María-Isabel Tejada; Carlos San Román; Luis Robles-Díaz; Miguel Urioste; Javier Benítez Journal: Breast Cancer Res Treat Date: 2008-02-27 Impact factor: 4.872
Authors: Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton Journal: Nat Genet Date: 2006-12-31 Impact factor: 38.330
Authors: Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes Journal: Proc Natl Acad Sci U S A Date: 2007-04-09 Impact factor: 11.205
Authors: William D Foulkes; Parviz Ghadirian; Mohammed Reza Akbari; Nancy Hamel; Sylvie Giroux; Nelly Sabbaghian; Andrew Darnel; Robert Royer; Aletta Poll; Eve Fafard; André Robidoux; Ginette Martin; Tarek A Bismar; Marc Tischkowitz; Francois Rousseau; Steven A Narod Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: Marc Tischkowitz; Marinela Capanu; Nelly Sabbaghian; Lili Li; Xiaolin Liang; Maxime P Vallée; Sean V Tavtigian; Patrick Concannon; William D Foulkes; Leslie Bernstein; Jonine L Bernstein; Colin B Begg Journal: Hum Mutat Date: 2012-02-15 Impact factor: 4.878
Authors: Eric C Dietze; Christopher Sistrunk; Gustavo Miranda-Carboni; Ruth O'Regan; Victoria L Seewaldt Journal: Nat Rev Cancer Date: 2015-02-12 Impact factor: 60.716
Authors: Yuan Chun Ding; Aaron W Adamson; Linda Steele; Adam M Bailis; Esther M John; Gail Tomlinson; Susan L Neuhausen Journal: Fam Cancer Date: 2018-04 Impact factor: 2.375